we partner with Health
Care Professionals to
support patients
through their
treatment cycle
2024_013EN01_May 2024
mimic the diverse real-life
exposure of respiratory
allergic patients1-3
demonstrated early 1st results
and meaningful improvements
over time for patients5-8
sublingual immunotherapy solution
that improves tolerability and
effectiveness for rhinitis patients
with or without controlled mild to
moderate asthma5-11
over 30 studies and has shown
carry-over effects for up to 6 years after
treatment cessation, even preventing
allergy worsening6*,11**
Highly potent based on allergen potency evaluated quantitatively without any validated clinical consequences.
**In this study Staloral® (Birch extract) was investigated as one product in a treatment group compared to a non-AIT
control group and is based on a retrospective German database analysis of health and prescription data.
P.E. (Physical Education)
teacher. The athletics and
birch-pollen seasons
overlap, this is when my
students need me the
most but my school work
and ability to concentrate
are impacted by my AR
(Allergic Rhinitis)."
circumstances. The treatment and the success of the therapy depicted represent an idealized
course. This possible course of therapy has been confirmed by clinical studies. Nevertheless, each
patient and each course of disease is highly individual and a corresponding effect cannot be
expected and guaranteed for all patients.
45 years old German
male, P.E. Teacher
Divorced, 3 children,
pets (cats, dogs)
Specialized in athletics
exclusively during the birch-
pollen season. Additionally, I
have developed OAS (Oral
Allergy Syndrome), leading to
oral itching when I consume
celery and fruits like apples,
pears, and plums. To manage
my AR, I rely on significant
amounts of symptomatic
medication. However, I am
currently facing challenges in
adequately preparing my
students for the local Junior
Athletics Championship."
For almost 15 years, he has been suffering
from violent itchy eyes and runny
nose
from March to
August with mild symptoms
in Autumn, he is particularly struggling
with
symptoms control in March-April.
After a few years without treatment, he
received oral H1-antihistamine
and
corticosteroids eye drops.
Later, he experiencedworsening of
rhinoconjunctivitis symptoms
associated
with fatigue, headache and oral syndrome
(lip swelling,
throat
discomfort) when
eating apples and was dispensed oral
corticosteroids.
mild itchy eyes and
runny nose
no wheeze
birch pollen with oral allergy
syndrome.
Birch pollen allergy associated
with the most bothersome
symptoms.
Recommendation
immunotherapy
liquid formulation
immunotherapy
tablet formulation
Symptomatic
Treatment
Sublingual immunotherapy
liquid formulation
my school colleagues in the park for
our annual BBQ end-of-school party, I
finally feel like I can achieve my full
potential in school and on the track
with my students!”
Results
AIT and I just had the best ever
early summer holiday with my
children. We went camping and zip-
lining in the forest. On our way
back home, we're going to spend
some more days in the campsite
near the city where I was born. It's
really good that I don't have to be
worried as before about allergies
when I go outside so I can show
them the places I grew in as a kid.”
sublingual immunotherapy solution
that optimises tolerability and
effectiveness for rhinitis patients
with or without controlled mild to
moderate asthma5-11
early 1st results and meaningful
improvements overt time for patients5-8
in over 30 studies and has
shown carry-over effects for
up to 6 years after treatment
cessation, even preventing
allergy worsening6**,11***
**Results compared Staloral (grass pollen extract) and Staloral (HDM extracts) with placebo, in a subpopulation of elderly (≥60 years of age) patients.
***In this study Staloral (Birch extract) was investigated as one product in a treatment group compared to a non-AIT control group and is based on a retrospective German database
analysis of health and prescription data.
reactions which can occur immediately after administration or be delayed.
As with any allergen immunotherapy, severe allergic reactions including
severe laryngopharyngeal disorder or systemic allergic reactions (i.e. acute
onset of an illness with involvement of the skin, mucosal tissue, or both,
respiratory compromise, persistent gastrointestinal symptoms, or reduced
blood pressure and/or associated symptoms) can occur.
Inform patients of the associated signs and symptoms and have them seek
immediate medical care and discontinue therapy should these occur.
Treatment should only be resumed at the instruction of a
physician. Please consult section 4.8 of the SmPC for full safety details.